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radiographic contrast agents and surgical antibiotic prophy-
laxis was presented to prescribers on the participating wards. 
Hospital pharmacists performed medication safety consulta-
tions, combining medication review of patients who are at 
risk for drug related problems with visits to ward physicians. 
Main outcome measure The outcome measure was the pro-
portion of the admissions of patients in which the physician 
did not adhere to one or more of the included guidelines. 
Difference was expressed in odds ratios (OR) with 95% 
confidence intervals (CI). Multivariable logistic regression 
analysis was performed. Results 1435 Admissions of 1378 
patients during the usual care period and 1195 admissions of 
1090 patients during the intervention period were included. 
Non-adherence was observed significantly less often during 
the intervention period [21.8% (193/886)] as compared to 
the usual care period [30.5% (332/1089)]. The adjusted OR 
was 0.61 (95% CI 0.49–0.76). Conclusion This study shows 
that education and support of the prescribing physician can 
reduce guideline non-adherence at surgical wards.
Keywords Education · Guideline adherence · Medication 
review · Patient safety · Prescribing · The Netherlands
Impacts on practice
• Pharmacotherapeutic guidelines seem to be poorly imple-
mented in daily clinical practice in Dutch hospitals.
• Hospital pharmacists can play a leading role in the imple-
mentation of key pharmacotherapeutic guidelines.
• Education on guidelines and support of the prescribing 
physician by the hospital pharmacist are an effective way 
to improve guideline adherence.
Abstract Background Despite the potential of clinical 
practice guidelines to improve patient outcomes, adherence 
to guidelines by prescribers is inconsistent. Objective The 
aim of the study was to determine whether an approach of 
introducing an educational programme for prescribers in the 
hospital combined with audit and feedback by the hospital 
pharmacist reduces non-adherence of prescribing physi-
cians to key pharmacotherapeutic guidelines. Setting This 
prospective intervention study with a before–after design 
evaluated patients at surgical, urological and orthopaedic 
wards. Method An educational program covering pain man-
agement, antithrombotics, fluid and electrolyte management, 
prescribing in case of renal insufficiency, application of 
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Introduction
Preventable, clinically relevant problems due to complex 
pharmacotherapy are common among hospitalised patients 
[1–4]. Examples are haemorrhage, arterial or venous 
thrombosis, drug intoxication in renal insufficiency, delir-
ium and faecal impaction. Many of these problems derive 
from prescribing errors that lead to potentially preventable 
morbidity, mortality and costs [5]. The majority of these 
are caused by pain medication, antithrombotics, antibacte-
rial drugs, cardiovascular drugs, and drugs that are renally 
excreted [1–3, 6–9].
Different strategies, including introduction of comput-
erized physician order entry (CPOE), pharmacist involve-
ment on the ward, educational programs and support sys-
tems for clinical decision making (CDS) have been studied 
to address this problem and to improve clinician prescrib-
ing in hospitalized patients [10–12].
Clinical practice guidelines with evidence-based recom-
mendations for physicians have been developed to assist 
doctors and to improve patient outcomes. In routine daily 
practice however, it appears to be difficult to implement 
key recommendations and guidelines seem to have limited 
impact on physician prescribing behaviour. Most clinicians 
can barely keep pace with the rapid advances in pharma-
cotherapy. And even if doctors are aware of the guidelines 
and are willing to change, to alter well established patterns 
of prescribing is difficult [13]. Earlier research showed that 
non-compliance to several guidelines by prescribers varies 
between 33 and 70% [14–16].
Several determinants of practice that prevent or enable 
guideline adherence, have been described. Guideline fac-
tors, such as quality of evidence and accessibility of the 
guideline, organizational factors and resources, such as 
the information system, frequent rotations of physicians 
on the ward and workload, patient factors such as increas-
ingly complex multi-morbidity and also individual health 
professional factors, such as knowledge and skills, aware-
ness and professional behaviour play a role [17, 18]. When 
these factors are taken into account in the development of 
strategies to improve guideline adherence, the quality of 
the treatment of hospitalised patients improves [19, 20].
Education is one of the possible strategies to tackle sev-
eral of these determinants for non-adherence. Education of 
prescribers is most effective when it is interactive and con-
tinuous, includes discussion of evidence and local consen-
sus and when it is followed by feedback on performance. 
This way of professional development needs to be built 
into patient care as much as possible, and should prefer-
ably take place in real time with clinical decision-support 
tools and patient-specific reminders to help doctors make 
the best decisions [21].
The P-REVIEW study is a prospective, multicentre, open 
intervention study, designed to investigate if an approach 
of introducing an educational programme for prescribers in 
the hospital combined with audit and feedback by the hos-
pital pharmacist can lead to a clinically relevant benefit for 
patients at surgical wards [22]. The educational program 
teaches the prescriber the pharmacological aspects of using 
high-risk drugs in high-risk patients. The hospital pharma-
cist suggests interventions based on a medication review of 
the patient. Guidelines are an important part of the educa-
tional program and the hospital pharmacist actively checks 
on and improves guideline adherence.
Aim of the study
The aim of the study was to determine whether an approach 
of introducing an educational programme for prescribers 
in the hospital combined with audit and feedback by the 
hospital pharmacist reduces non-adherence of prescribing 
physicians to key pharmacotherapeutic guidelines.
Ethics approval
The institutional review boards of the Isala Hospital (Zwolle, 
the Netherlands) and the Meander Medical Centre (Amers-
foort, the Netherlands) stated that the study was exempt from 
ethical approval. Patients’ data were collected and stored in 
accordance with prevailing privacy regulations.
Methods
Study design and setting
The P-REVIEW study was an open intervention study with 
a before-after design performed in two large general teach-
ing hospitals in the Netherlands (the Isala Hospital (779 
beds), and the Meander Medical Centre (600 beds)) [22]. 
After a 6-month control period (usual care) the intervention 
was introduced during 3 months. This was followed by a 
6-month intervention period. This sub-study on guideline 
adherence was performed during the fifth month of the usual 
care period and the fifth month of the intervention period.
Study population
Patients who were admitted to the surgical, urological and 
orthopaedic wards of the two hospitals during the study 
period were included. Guideline non-adherence was meas-
ured in all these patients. Patients were followed up until 
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discharge. Patients could be included more than once, in 
case of readmission in the study period. Day care patients 
were excluded.
Usual care
During the usual care period the normal procedures of med-
ication surveillance and communication between hospital 
pharmacists and physicians were maintained. A CPOE and 
CDS system was applied in both hospitals.
Hospital pharmacists checked medication of all patients 
on a daily basis with the aid of computer-generated alerts 
based on a national database (“G-standard”) [23]. They 
could warn the physician by telephone or in case the advice 
was less urgent send a an advice on paper to the ward. In 
both hospitals, pharmacists were supported by a same set 
of computerised “clinical rules” to screen for specific pre-
scribing errors. These clinical rules are based on pharma-
cotherapeutic guidelines and combine clinical patient data 
(like renal function and electrolyte abnormalities) with 
medication specific factors: dose adjustments in case of 
renal insufficiency; hypokalemia in patients using diuretic; 
hyperkalemia in patients using potassium-saving diuretics, 
ACE inhibitor, trimethoprim or NSAID; hyponatremia in 
patients using SSRI, thiazide or carbamazepine; folic acid 
to be added to methotrexate; dosing of oral cytostatics; PPI 
to be added in case of NSAID [24].
Intervention
During the intervention phase, a combination of an educa-
tional program and medication counselling for prescribers 
on the wards took place.
An educational program covering pain management, 
antithrombotics, fluid and electrolyte management, pre-
scribing in the case of renal insufficiency, application of 
radiographic contrast agents and surgical antibiotic prophy-
laxis was developed. National and local hospital guidelines 
related to these subjects were also included [25–32]. The 
program consisted of two parts of approximately 2 h each. 
All prescribers, who provided medical care on the partici-
pating wards during the intervention period, attended the 
course.
In addition, hospital pharmacists were trained to per-
form medication safety consultations (MSC), combining 
medication reviews and a visit to audit and give feedback 
to prescribers on the ward by an internist clinical phar-
macologist and a hospital pharmacist with specific exper-
tise in this area. Medication reviews were performed in 
high-risk patients, who were identified with a computer-
ised screening method. The screening method was based 
on recent literature on prescription errors and targeted 
patients at risk for potentially preventable, drug-related 
problems. This screening method and a checklist for per-
forming medication review on surgical wards is described 
before by Bos et al. [22]. In the weekly visits of the hospi-
tal pharmacist to the physician on the surgical ward, there 
was special attention for adherence to important pharma-
cotherapeutic guidelines that were addressed in the edu-
cational program. Feedback was given based on the medi-
cation reviews to the prescriber. The attended issues and 
advices were discussed in a broader context and hospital 
pharmacists clarified the pharmacological background and 
related prevailing hospital guidelines.
Guidelines
In order to be able to score guideline non-adherence ten 
recommended pharmacotherapeutic measures were derived 
from several guidelines (Table 1).
The guidelines were selected by a group of experts, 
including hospital pharmacists, clinical pharmacologists 
and hospital-based physicians in a consensus meeting. The 
selected guidelines had to relate to medication that has 
shown to frequently be involved in preventable, clinically 
relevant, drug-related problems [1–3, 6–8]. All guidelines 
had to be part of a local implemented protocol in the hospital 
and were addressed in the educational program.
Study endpoints
The primary outcome measure of guideline non-adherence 
was the proportion of the admissions of patients in which the 
physician did not adhere to one or more of the guidelines. 
The secondary outcome measures were the proportions of 
admissions of patients in which the physician did not adhere 
to each of ten guidelines.
Data collection
Collected data included patient characteristics, laboratory 
and medication data, as well as transfers to other wards, 
medical correspondence and medical interventions. Data 
regarding radiology, microbiology, blood transfusion and 
information about medical incidents were also collected. 
Part of the requisite data could not be collected automati-
cally. Therefore, a trained research assistant collected data 
manually from the medical records of the patients using a 
predefined protocol. These data included whether the patient 
had had surgery, type of surgery and whether the patient had 
an indication for thrombosis prophylaxis, antibiotics prophy-
laxis or endocarditis prophylaxis.
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A validated multisource Microsoft Access database 
(Microsoft version 2003) was used.
Sample size and data analysis
The PREVIEW-study has been powered on the outcome 
measure of reduction of clinically relevant, potentially pre-
ventable drug-related problems. For the power of this sub-
study on guideline adherence, we studied earlier research on 
this subject showing that non-compliance to several guide-
lines by prescribers varies between 33 and 70% [14–16]. 
Earlier studies that describe interventions that aim to 
improve guideline adherence showed results on improve-
ment of adherence varying form 50–60 to 65–80% [19, 20]. 
To detect a reduction from 30% non-adherence to 20% non-
adherence, 313 patients had to be included in each group. 
Because the primary outcome measure of the P-REVIEW 
study (adverse drug events) needed a very large patient 
cohort to detect a significant difference, we assumed that 
measuring during 1 month in both periods would generate 
enough power for this sub-study on guideline adherence.
Baseline characteristics were presented as means and 
standard deviation or percentages for continuous or dichoto-
mous outcomes, respectively.
Differences between groups were expressed in odds ratios 
with 95% confidence intervals and were tested for statisti-
cal significance using independent t test or Chi square tests, 
as appropriate. P < 0.05 was considered to be statistically 
significant.
In order to correct for possible confounding, multivari-
able logistic regression analysis was performed. The fol-
lowing possible confounders were initially entered into the 
model: age, gender, department of admission, number of 
medicines on the first day after admission and pharmaco-
therapeutic group of these medicines, length of stay and 
renal function. Those that showed no clear relation with the 
outcome (p > 0.10) were removed, but only in case their 
removal did not alter the relation under study (OR on non-
adherence in usual care period vs intervention period) by 
more than 10%.
Statistical analyses were performed using SPSS Statistics 
version 22 (IBM Software, New York).
Results
In the usual care period of the study 1435 admissions (1378 
patients) and in the intervention period 1195 admissions 
(1090 patients) were included.
Table 2 details the characteristics of these patients. There 
was no difference between the two groups in age, gender, 
department of admission or in the number of medications on 
the first day after admission. Also, there was no difference in 
use of medication, length of hospital stay and the proportion 
of patients with renal insufficiency.
Table 3 shows the proportions of admissions of patients 
in which the physician did not adhere to the guidelines in the 
usual care period and in the intervention period, respectively. 
In 1089 admissions of 1069 patients in the usual care period 
and in 886 admissions of 864 patients in the intervention 
period, one or more included guidelines were applicable. 
Figure 1 shows a forest plot in which the odds ratios for 
non-adherence are presented.  
A significantly lower proportion of admissions of 
patients in which the physician did not adhere to the pre-
vailing guidelines occurred in the intervention period 
(21.8% (193/886) compared to the usual care period [30.5% 
(332/1089)] (p < 0.05). The odds ratio (OR) was 0.64 (95% 
CI 0.52–0.78).
After correction for possible confounders, the adjusted 
OR was 0.61 (95% CI 0.49–0.76).
When the analysis was conducted with protocol non-
adherence as denominator (total number of times that a 
guideline had to be followed by a prescriber) instead of 
admissions, results were comparable. [13.5% (211/1564) in 
the intervention period compared to 18.6% (368/1976) in the 
usual care period (p ≤ 0.05)]. The odds ratio (OR) was 0.68 
(95% CI 0.57–0.82).
Discussion
Our study shows that education and support of the prescrib-
ing physician with respect to high-risk patients in surgical 
departments can lead to reduced pharmacotherapeutic guide-
line non-adherence among prescribing physicians. Achieved 
effects were obtained on top of the effect of other measures 
as CPOE/CDS system and clinical rules, which were part 
of usual care.
Earlier studies describe interventions that aim to improve 
guideline adherence in the hospital. Hogli et al. describe an 
intervention study, reporting distribution of a recently pub-
lished pocket version of the national guideline. This led to a 
substantial increase in prescribing of appropriate empirical 
antibiotics from 61.7 to 83.8% [20]. Schouten et al. imple-
mented a multifaceted guideline-implementation strategy, 
considering the barriers of implementation of guidelines. 
They found an increase of the rate of guideline adherence of 
antibiotic prescription from 50.3 to 64.3% [19].
In the two hospitals that participated in this study, the 
guidelines targeted in our study had already been imple-
mented. Nevertheless, we found that in nearly one third 
of cases physicians were non-adherent to the local hospi-
tal guidelines. This is in line with earlier research on this 
subject. Van den Bemt et al. found that the proportion of 
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admissions not compliant with guidelines on gastric protec-
tion in case of use of NSAID in hospitalized surgical patients 
was 46.6% [16]. Drenth et al. found an adherence of 53.9% 
with a dosing guideline in patients with impaired renal func-
tion at hospital discharge [15]. Schilp et al. studied adher-
ence to the guideline concerning identification and hydration 
of high-risk patients for contrast-induced nephropathy in dif-
ferent hospitals and found that only two third of the high-
risk patients were hydrated before contrast administration 
[33]. Huijts et al. reported proportions of patients receiving 
guideline-adherent antibiotics for community acquired pneu-
monia from 30.5 to 62.9% [34].
Educating prescribers is a measure that can be taken on 
top of other measures to improve guideline adherence. Edu-
cating prescribers is only effective if it is a part of a multi-
faceted intervention [35]. Novel of the P-REVIEW educa-
tion program is the combination with a weekly visit by the 
hospital pharmacist, who audited and improved guideline 
adherence. We aimed to boost the effect of the education 
program by the weekly visits of the hospital pharmacist. 
We previously showed that these weekly visits were feasi-
ble and also efficient. We hypothesized that the support by 
education of the prescriber by the hospital pharmacist in 
a more pro-active role is more efficient and effective than 
the traditional retrospective role of the hospital pharmacist 
in medication surveillance [22]. In this study we show that 
this intervention can lead to a significant decrease in non-
adherence of guidelines, although there may be still room 
for improvement.
The study has several strengths.
The study was performed in two representative general 
teaching hospitals. The intervention was easily implemented, 
since both education and weekly visits were performed by 
Table 2  Characteristics of admitted patients
LMWH low molecular weight heparin, RAS renin angiotensin system, NSAIDs non-steroidal anti-Inflammatory drugs
Usual care period Intervention period p value
No. of admissions 1435 1195
No. of patients 1378 1090
Mean age of patients in years ± SD 63.8 ± 17.2 63.3 ± 17.1 0.406
Gender of patients, n (%) female 720 (50.2%) 599 (50.1%) 0.980
Department of admission 0.605
 General surgery, n (%) 852 (59.4%) 682 (57.1%)
 Orthopaedic surgery, n (%) 328 (22.9%) 294 (24.6%)
 Urology, n (%) 255 (17.8%) 219 (18.3%)
Mean no. of medications the first day after admission, ± SD 6.9 ± 5.5 7.2 ± 5.8 0.233
Medication the first day after admission, n (%)
 Hypoglycemics 178 (12.4%) 156 (13.1%) 0.618
 Vitamin K antagonists 149 (10.4%) 117 (9.8%) 0.616
 Heparin/LMWH 951 (66.3%) 773 (64.7%) 0.394
 Thrombocyte aggregation inhibitors 284 (19.8%) 238 (19.9%) 0.936
 Diuretics 337 (23.5%) 287 (24.0%) 0.749
 Beta blockers 391 (27.2%) 305 (25.5%) 0.318
 Calcium channel blockers 146 (10.2%) 142 (11.9%) 0.162
 RAS inhibitors 375 (26.1%) 317 (26.5%) 0.819
 NSAIDs 485 (33.8%) 424 (35.5%) 0.366
 Opioids 601 (41.9%) 491 (41.1%) 0.681
 Antipsychotics 90 (6.3%) 79 (6.6%) 0.724
Mean length of stay, days ± SD
 General surgery 7.7 ± 9.7 7.0 ± 8.3 0.154
 Orthopaedic surgery 7.6 ± 8.6 6.7 ± 6.5 0.107
 Urology 4.3 ± 4.8 4.4 ± 4.1 0.798
MDRD eGFR of patients (ml/min/1.73 m2), n (%) (n = 1016*) (n = 836*) 0.476
 < 10 4 (0.4%) 1 (0.1%)
 10–30 43 (4.2%) 39 (4.7%)
 30–60 227 (22.3%) 203 (24.3%)
 > 60 742 (73.0%) 593 (70.9%)
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health care providers already active in the hospital and the 
intervention did not lead to additional costs.
The intervention combines different strategies. These 
strategies address different factors that have been described 
to impair quality of care and can influence guideline adher-
ence [17].
By educating the prescriber in the hospital and teaching 
the prescriber during medication safety consultation, the 
knowledge and skills needed to adhere to guidelines will 
improve. Also the attitude towards guidelines in general 
and motivation to adhere may improve. This study how-
ever, didn’t collect qualitative data from the prescribers to 
support this hypothesis, and this would be useful to integrate 
in future research.
These weekly visits of the hospital pharmacist can be 
considered as a continuous form of workplace-based educa-
tion. This addresses the problem that a short-term education 
programme has been found to have only a transient effect on 
the frequency of prescribing errors [36].
There are some limitations as well. We selected ten rel-
evant pharmacotherapeutic measures derived from several 
guidelines. This selection was not complete, and our results 
may not be generalisable to other or all guidelines. Also, the 
study was performed in two hospitals, which might limit the 
external validity of the study.
Table 3  Non-adherence of prescribers to pharmacotherapeutic measures based on prevailing guidelines
a  OR, adjusted for confounders
b  Statistical significant
Usual care period (n = 1435) Interven-
tion period 
(n = 1195)
Odds ratios and con-
fidence intervals
Non-adherence Non-adherence OR 95% CI
1. Perioperative thrombosis prophylaxis if indicated? 22/590 (3.7%) 10/490 (2.0%) 0.54 0.25–1.15
2. Perioperative bridging of antithrombotics if indicated? 2/48 (4.2%) 2/46 (4.3%) 1.05 0.14–7.75
3. In case of NSAID use, ppi added if indicated? 5/101 (5.0%) 3/83 (3.6%) 0.72 0.17–3.11
4. In case of opioid use, laxative added if indicated? 154/296 (52%) 62/190 (32.6%) 0.45b 0.31–0.65
5. In case of impaired renal function (MDRD < 30), no use of NSAID? 8/50 (16.0%) 4/40 (10.0%) 0.54 0.15–1.94
6. In case of radiocontrast, diuretics discontinued? 16/23 (69.6%) 20/29 (69.0%) 0.97 0.30–3.18
7. In case of radiocontrast, NSAID discontinued? 17/25 (68.0%) 15/20 (75.0%) 1.41 0.38–5.26
8. In case of radiocontrast and MDRD < 60, metformin discontinued? 2/3 (66.7%) 2/2 (100.0%) 0.33 0.01-12.79
9. Perioperative antibiotics prophylaxis, if indicated? 136/832 (16.3%) 93/661 (14.1%) 0.84 0.63–1.12
10. Perioperative endocarditis prophylaxis, if indicated? 6/8 (75%) 0/3 (0%) 0.05 0.00–1.50
 Overall non-adherence 332/1089 (30.5%) 193/886 (21.8%) 0.64b 0.52–0.78
0.61a,b 0.49–0.76
Fig. 1  Forest plot of non-adher-
ence of prescribers to pharma-
cotherapeutic measures based 
on prevailing guidelines
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This study was not a randomised controlled study, but was 
performed in a before after design, introducing the possibil-
ity of confounding. Therefore, to adjust for confounding, we 
performed a multivariable logistic regression analysis. Yet, 
we may not have identified all potential confounders.
We defined the outcome measure as the proportion of 
the admissions of patients in which the physician did not 
adhere to one or more of the guidelines. We assumed that 
in every single admission a physician has to follow all 
guidelines. When a patient is readmitted, the treating phy-
sician is often different and guidelines can be different 
from an early admission of the patient. On the other hand 
adherence on guidelines in an early admission can lead to 
(not intended) adherence in a readmission.
For each guideline we only included these cases in 
which there was no possible discussion on adherence 
(Table 1). By specifying the cases, we minimized the pos-
sibility of intended non-adherence by the physician.
The P-REVIEW study describes 106 admissions with 
one or more clinically relevant, potentially preventable, 
drug-related events in the usual care period and 73 in the 
intervention period [22]. These drug-related events are 
divided into different types of events, such as haemor-
rhage, thrombosis, renal failure related events, central 
nervous systems events, faecal impaction, hypoventilation 
and a group of unclassifiable events [22]. We noted that 
25 of the 106 events in the usual care period and 15 of the 
73 events in the intervention period relate to the studied 
guidelines and could possibly have been prevented in case 
of better guideline adherence. That means that only a mod-
est part of the positive effect on these events can be related 
to an improvement in adherence of the studied guidelines.
This suggests that improving guideline adherence will 
have only limited effect and it may not be necessary to 
pursue 100% adherence. It may be better not to focus on 
guideline adherence or implementation of clinical rules 
alone, but on a comprehensive medication review of high 
risk patients, in which a check on adherence of guidelines 
and clinical rules is integrated.
Given the limited resources in healthcare, we think this 
could be an important question for future research.
Conclusions
In summary, this study shows that education and support 
of the prescribing physician with respect to high-risk 
patients in surgical departments leads to an improvement 
of guideline adherence among prescribing physicians.
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